SHA-68

Last updated
SHA-68
SHA-68 structure.png
Clinical data
ATC code
  • none
Identifiers
  • N-[(4-fluorophenyl)methyl]-3-oxo-1,1-diphenyl-5,6,8,8a-tetrahydro-[1,3]oxazolo[3,4-a]pyrazine-7-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C26H24FN3O3
Molar mass 445.494 g·mol−1
3D model (JSmol)
  • c4ccccc4C1(c5ccccc5)OC(=O)N3C1CN(CC3)C(=O)NCc(cc2)ccc2F
  • InChI=1S/C26H24FN3O3/c27-22-13-11-19(12-14-22)17-28-24(31)29-15-16-30-23(18-29)26(33-25(30)32,20-7-3-1-4-8-20)21-9-5-2-6-10-21/h1-14,23H,15-18H2,(H,28,31)
  • Key:SFRQIPRTNYHJHP-UHFFFAOYSA-N
   (verify)

SHA-68 is a drug which acts as a selective, non-peptide antagonist at the neuropeptide S receptor NPSR. In animal studies it reduced motor stereotypes, and blocks the stimulant action of neuropeptide S. [1] [2]

Contents

Synthesis

The synthesis of SHA-68 was shown in a patent (ref example 1, Ex 1, Ex 2, Ex 16). [3]

SHA-68 synthesis.svg

The Grignard reaction between Methyl 2-piperazine carboxylate [2758-98-7] (1) and phenylmagnesium bromide [100-58-3] (2) occurs to give alpha,alpha-Diphenyl-2-piperazinemethanol [17532-20-6] (3). {This compound is called Azapipradrol}. Protection of the sterically more accessible piperazine nitrogen with Boc anhydride occurs to give PC23122074 (4). Treatment with ethyl chloroformate [541-41-3] (5) gives the cyclic urethane and hence, PC68420957 (6). Deprotection of the Boc group in the presence of trifluoroacetic acid gave 1,1-Diphenyltetrahydro-1H-oxazolo[3,4-a]pyrazin-3(5H)-one [847555-93-5] [847556-28-9] (7). Lastly, treatment with 4-fluorophenyl isocyanate [1195-45-5] (8) gave the substituted urea, thus completing the synthesis of SHA-68 (9).

SAR reveals similarity to RTI-118 & contains the same precursor.

See also

References

  1. ↑ Fukatsu K, Nakayama Y, Tarui N, Mori M, Matsumoto H, Kurasawa O, Banno H. Bicyclic Piperazine Compound and Use Thereof. PCT Patent WO 2005/021555 A1. Published 26.08.2004
  2. ↑ Okamura N, Habay SA, Zeng J, Chamberlin AR, Reinscheid RK (June 2008). "Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor". The Journal of Pharmacology and Experimental Therapeutics. 325 (3): 893–901. doi:10.1124/jpet.107.135103. PMC   2583099 . PMID   18337476.
  3. ↑ Kohji Fukatsu, et al. WO2005021555 (to Takeda Pharmaceutical Co Ltd).


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.